In a significant breakthrough in the global fight against antimicrobial resistance (AMR), researchers at the Indian Institute of Technology (IIT) Roorkee, led by Professor Ranjana Pathania, have developed Compound 3b—a novel drug candidate that restores the effectiveness of the powerful antibiotic Meropenem against the highly drug-resistant bacterium Klebsiella pneumoniae.
Klebsiella pneumoniae, a Gram-negative pathogen, is responsible for severe infections such as pneumonia, bloodstream infections, and urinary tract infections. It is listed among the World Health Organization’s top-priority pathogens due to its growing resistance to last-resort antibiotics, making treatment extremely difficult and life-threatening.
The Mechanism of Action
Over time, Klebsiella pneumoniae has evolved enzymes—specifically carbapenemases—that break down carbapenem antibiotics like Meropenem, rendering them ineffective. Compound 3b works by neutralising these destructive bacterial enzymes, preventing them from degrading the antibiotic. When combined with Meropenem, the drug regains its full potency, effectively killing the bacteria.
Importantly, the IIT Roorkee team reports that Compound 3b demonstrates high specificity, targeting only the bacterial enzymes without harming beneficial bacteria or healthy human cells. Laboratory testing confirmed its safety profile for human cell lines, making it a promising candidate for further development.
Promising Preclinical Results
The team tested the combination therapy in preclinical lung infection models, simulating real-life scenarios of severe bacterial infections. The results were highly encouraging, with the combination of Compound 3b and Meropenem significantly reducing bacterial load and improving survival rates in infected models. This approach not only revived Meropenem’s therapeutic effectiveness but also reduced the likelihood of the bacteria developing further resistance.
Addressing a Global Health Crisis
Antimicrobial resistance is one of the most pressing health threats of the 21st century. Without effective antibiotics, even common infections could become lethal, and critical medical procedures such as surgeries, chemotherapy, and organ transplants could carry life-threatening risks due to untreatable infections. According to the WHO, AMR already causes over 1.27 million deaths globally each year, with projections warning of a potential 10 million deaths annually by 2050 if urgent action is not taken.
By reviving the effectiveness of an existing, potent antibiotic rather than relying solely on the lengthy process of discovering entirely new drugs, Compound 3b offers a faster and more cost-effective route to saving lives. This strategy—known as antibiotic adjuvant therapy—is increasingly seen as a key weapon in the battle against drug-resistant bacteria.
The IIT Roorkee research team is now working on advancing Compound 3b to clinical trials. If successful, the combination therapy could be used in hospitals worldwide to treat life-threatening Klebsiella pneumoniae infections and potentially other Gram-negative pathogens with similar resistance mechanisms.
This pioneering discovery not only positions India at the forefront of AMR research but also offers fresh hope in an escalating global health emergency. As Professor Pathania and her team continue their work, the world watches with anticipation for a future where deadly superbugs can once again be defeated.
